
Figure 1:


Trial 1
Trial 2
A
WASO
LSM change from baseline, min (95% CI)
p<0.001
p<0.001
p<0.001
p<0.001
No. of patients Baseline Month 1 Month 3
Placebo 310 299 283
Daridorexant 25 mg 310 298 289
Daridorexant 50 mg 310 305 287
B
WASO
p<0.001
p=0.0028
No. of patients Baseline Month 1 Month 3
Placebo 308 300 283
Daridorexant 10 mg 307 302 278
Daridorexant 25 mg 309 295 281
C
LPS
p<0.001
p=0.0015
p<0.001
p<0.001
No. of patients Baseline Month 1 Month 3
Placebo 310 299 283
Daridorexant 25 mg 310 298 289
Daridorexant 50 mg 310 305 287
D
LPS
No. of patients Baseline Month 1 Month 3
Placebo 308 300 283
Daridorexant 10 mg 307 302 278
Daridorexant 25 mg 309 295 281
E
sTST
p<0.001
p<0.001
p=0.0334
p=0.0013
No. of patients Baseline Month 1 Month 3
Placebo 310 302 289
Daridorexant 25 mg 310 303 292
Daridorexant 50 mg 310 304 289
F
sTST
p<0.001
p<0.001
No. of patients Baseline Month 1 Month 3
Placebo 308 297 287
Daridorexant 10 mg 307 304 289
Daridorexant 25 mg 309 297 285
G
IDSIQ sleepiness domain
p<0.001
p<0.001
No. of patients Baseline Month 1 Month 3
Placebo 310 301 288
Daridorexant 25 mg 310 301 290
Daridorexant 50 mg 310 304 291
H
IDSIQ sleepiness domain
No. of patients Baseline Month 1 Month 3
Placebo 308 297 289
Daridorexant 10 mg 307 304 286
Daridorexant 25 mg 309 297 283
Placebo
Daridorexant 10 mg
Daridorexant 25 mg
Daridorexant 50 mg